Berberine inhibits dyslipidemia in C57BL/6 mice with lipopolysaccharide induced inflammation

Pharmacological Reports

Volumn 64, Issue 4, 2012, Pages 889-895

  Xiao, Hong Bo ^a   Sun, Zhi Liang ^a   Zhang, Heng Bo ^b   Zhang, Da Sheng ^a  

^a HUNAN AGRICULTURAL UNIVERSITY   (China)

^b Furong District Red Cross Hospital   (China)

Author keywords

Berberine; Low density lipoprotein receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

8 ISOPROSTANE; BERBERINE; CYTOKINE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1ALPHA; LIPID; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG MECHANISM; DYSLIPIDEMIA; FEMALE; LIPID BLOOD LEVEL; METABOLIC PARAMETERS; MOUSE; NONHUMAN; POLYSACCHARIDE INDUCED INFLAMMATION; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84867676713     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(12)70883-6     Document Type: Article

References (31)

1. Affuso F, Mercurio V, Fazio V, Fazio S: Cardiovascular and metabolic effects of Berberine. World J Cardiol, 2010, 2, 71-77.
2. Baltazar MT, Dinis-Oliveira RJ, Duarte JA, Bastos ML, Carvalho F: Antioxidant properties and associated mechanisms of salicylates. Curr Med Chem, 2011, 18, 3252-3264.
3. Battu SK, Repka MA, Maddineni S, Chittiboyina AG, Avery MA, Majumdar S: Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS PharmSciTech, 2010, 11, 1466-1475.
4. Brando Lima AC, Machado AL, Simon P, Cavalcante MM, Rezende DC, Sperandio da Silva GM, Nascimento PG et al.: Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacol Rep, 2011, 63, 1029-1039.
5. Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 2003, 34, 154-156. (Pubitemid 36666925)
6. Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE: Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis, 2008, 201, 266-273.
7. Cao G, Qian YW, Kowala MC, Konrad RJ: Further LDL cholesterol lowering through targeting PCSK9 for coronary artery disease. Endocr Metab Immune Disord Drug Targets, 2008, 8, 238-243.
8. Cariou B, Ouguerram K, Zad'r Y, Guerois R, Langhi C, Kourimate S, Benoit I et al.: PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol, 2009, 29, 2191-2197.
9. Dubuc G, Chamberland A, Wassef H, Davignon J, Seidah NG, Bernier L, Prat A: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol, 2004, 24, 1454-1459. (Pubitemid 39050440)
10. Duff CJ, Hooper NM: PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets, 2011, 15, 157-168.
11. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun, 2008, 374, 341-344.
12. Holy EW, Akhmedov A, Lüscher TF, Tanner FC: Berberine, a natural lipid-lowering drug, exerts prothrombotic effects on vascular cells. J Mol Cell Cardiol, 2009, 46, 234-240.
13. Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW: Sterol-dependent regulation of proprotein convertase subtilisin/ kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res, 2008, 49, 399-409. (Pubitemid 351213625)
14. Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C: Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res, 2004, 45, 1169-1196. (Pubitemid 38802622)
15. Konrad RJ, Troutt JS, Cao G: Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis, 2011, 10, 38.
16. Kotani K, Yamada T, Miyamoto M, Ishibashi S, Taniguchi N, Gugliucci A: Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients. Pharmacol Rep, 2012, 64, 212-216.
17. Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN et al.: Secreted PCSK9 decreases LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest, 2006, 116, 2995-3005. (Pubitemid 44684484)
18. Li L, Thompson PA, Kitchens RL: Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene: role of hepatic LDL receptors. J Lipid Res, 2008, 49, 1782-1793.
19. Liao W, Rudling M, Angelin B: Endotoxin suppresses rat hepatic low-density lipoprotein receptor expression. Biochem J, 1996, 313, 873-878. (Pubitemid 26050822)
20. Lopez D: Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia. Drug News Perspect, 2008, 21, 323-330.
21. Mayer G, Poirier S, Seidah NG: Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J Biol Chem, 2008, 283, 31791-3801.
22. Memon RA, Staprans I, Noor M, Holleran WM, Uchida Y, Moser AH, Feingold KR, Grunfeld C: Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol, 2000, 20, 1536-1542. (Pubitemid 30353885)
23. Paim BA, Velho JA, Castilho RF, Oliveira HC, Vercesi AE: Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. Free Radic Biol Med, 2008, 44, 444-451.
24. Rashid S, Curtis DE, Garuti R, Anderson NN, Bashmakov Y, Ho YK, Hammer RE et al.: Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci USA, 2005, 102, 5374-5379. (Pubitemid 40530265)
25. Sarna LK, Wu N, Hwang SY, Siow YL: Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. Can J Physiol Pharmacol, 2010, 88, 369-378.
26. Sasaki H, Balto K, Kawashima N, Eastcott J, Hoshino K, Akira S, Stashenko P: Gamma interferon (IFN-γ) and IFN-γ-inducing cytokines interleukin-12 (IL-12) and IL-18 do not augment infection-stimulated bone resorption in vivo. Clin Diagn Lab Immunol, 2004, 11, 106-110. (Pubitemid 38090661)
27. Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A et al.: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA, 2003, 100, 928-933. (Pubitemid 36183932)
28. Steinberg D, Witztum JL: Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels. Proc Natl Acad Sci USA, 2009, 106, 9546-9547.
29. Wang Y, Jia X, Ghanam K, Beaurepaire C, Zidichouski J, Miller L: Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis, 2010, 209, 111-117.
30. Zhang S, Zhang B, Dai W, Zhang X. Oxidative damage and antioxidant responses in Microcystis aeruginosa exposed to the allelochemical berberine isolated from golden thread. J Plant Physiol, 2011, 168, 639-643.
31. Zhou JY, Zhou SW, Zhang KB, Tang JL, Guang LX, Ying Y, Xu Y et al.: Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. Biol Pharm Bull, 2008, 31, 1169-1176. (Pubitemid 351871171)